Acetyl-L-Carnitine in the Treatment of Septic Shock

Vanderbilt University13 enrolled

Overview

This placebo-controlled study investigates acetyl-L-carnitine in the treatment of septic shock requiring vasopressors.

This is a cross-over study which infuses ALC for 12 out of 18 hours (and placebo the other 6). Patients must have vasopressor-dependent septic shock and be free from renal failure, hepatic failure, and seizures to be eligible.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Septic Shock

Interventions

Acetyl-L-CarnitineDRUG

Acetyl-L-Carnitine - 4 g IV over 30 minutes, then 8 g iv over the next 12 hours

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * documented or presumed infection * shock requiring vasopressors Exclusion Criteria: * dialysis * hepatic failure * seizures

Locations (1)

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Outcomes

Primary Outcomes

Mean Arterial Blood Pressure

Mean Arterial blood pressure measured non-invasively at 18 hours

Time frame: 18 hours

Secondary Outcomes

Vasopressor Dose

Change in vasopressor dose between 6 and 24 hours.

Time frame: 6-24 hours

Serum Lactate

Latest serum lactate between 12 and 36 hours

Time frame: 12-36 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.